Close

Ratings by RBC Capital (Leonid Timashev)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
5/14/2024 Legend Biotech Corp. LEGN Maintain Outperform
(N/A)
 
 
  Details
5/10/2024 Biohaven Pharmaceutical Holding BHVN Maintain Outperform
(N/A)
 
 
  Details
4/22/2024 Edgewise Therapeutics EWTX Maintain Outperform
(N/A)
 
 
  Details
3/1/2024 Biohaven Pharmaceutical Holding BHVN Maintain Outperform
(N/A)
 
 
  Details
2/28/2024 NewAmsterdam Pharma Co NV NAMS Maintain Outperform
(N/A)
 
 
  Details
2/21/2024 Axsome Therapeutics AXSM Maintain Outperform
(N/A)
 
 
  Details
2/16/2024 Biohaven Pharmaceutical Holding BHVN New Coverage Outperform
(N/A)
49.11
(37.37)
-23.91% Details
1/25/2024 Axsome Therapeutics AXSM New Coverage Outperform
(N/A)
91.78
(76.54)
-16.6% Details
11/14/2023 Design Therapeutics Inc DSGN Maintain Sector Perform
(N/A)
 
 
  Details
10/30/2023 NewAmsterdam Pharma Co NV NAMS New Coverage Outperform
(N/A)
6.31
(20.09)
218.38% Details
9/5/2023 Pyxis Oncology Inc. PYXS New Coverage Outperform
(N/A)
2.32
(4.15)
78.88% Details
8/15/2023 Design Therapeutics Inc DSGN Downgrade Sector Perform
(Outperform)
7.33
(4.41)
-39.84% Details
5/18/2023 Legend Biotech Corp. LEGN Maintain Outperform
(N/A)
 
 
  Details
5/10/2023 Design Therapeutics Inc DSGN Maintain Outperform
(N/A)
 
 
  Details
3/24/2023 Legend Biotech Corp. LEGN New Coverage Outperform
(N/A)
43.82
(45.16)
3.06% Details
12/8/2022 Design Therapeutics Inc DSGN Maintain Outperform
(N/A)
 
 
  Details
11/4/2022 Edgewise Therapeutics EWTX Maintain Outperform
(N/A)
 
 
  Details
11/4/2022 Design Therapeutics Inc DSGN Maintain Outperform
(N/A)
 
 
  Details
5/2/2022 Design Therapeutics Inc DSGN New Coverage Outperform
(N/A)
11.94
(4.41)
-63.07% Details
4/13/2022 Edgewise Therapeutics EWTX New Coverage Outperform
(N/A)
8.52
(18.11)
112.56% Details